NeuroSense Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
16
- Stock Symbol
-
NRSN
- Share Price
-
$1.22
- (As of Wednesday Closing)
NeuroSense Therapeutics General Information
Description
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Contact Information
Website
www.neurosense-tx.comCorporate Office
- One Broadway
- Cambridge, MA
- United States
Corporate Office
- One Broadway
- Cambridge, MA
- United States
NeuroSense Therapeutics Timeline
NeuroSense Therapeutics Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.22 | $1.22 | $0.40 - $2.33 | $24.2M | 19.8M | 310K | -$0.65 |
NeuroSense Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 19,521 | 6,053 | 5,971 | 25,927 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (11,011) | (11,350) | (12,327) | (4,038) |
| Net Income | (10,971) | (11,280) | (12,340) | (4,041) |
| Total Assets | 1,841 | 3,176 | 7,710 | 11,431 |
| Total Debt | 36 | 142 | 211 | 0 |
NeuroSense Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
NeuroSense Therapeutics Comparisons
Industry
Financing
Details
NeuroSense Therapeutics Competitors (7)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Prilenia | Venture Capital-Backed | Herzliya, Israel | ||||
| Amylyx | Formerly VC-backed | Cambridge, MA | ||||
| Prothena | Corporation | Dublin, Ireland | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| AB Science | Formerly Accelerator/Incubator backed | Paris, France |
NeuroSense Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NeuroSense Therapeutics Patents
NeuroSense Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230120880-A1 | Compositions comprising ciprofloxacin and celecoxib | Active | 19-Oct-2021 | ||
| CA-3235348-A1 | Compositions comprising ciprofloxacin and celecoxib | Pending | 19-Oct-2021 | ||
| AU-2022370513-A1 | Compositions comprising ciprofloxacin and celecoxib | Pending | 19-Oct-2021 | ||
| EP-4419099-A1 | Compositions comprising ciprofloxacin and celecoxib | Pending | 19-Oct-2021 | ||
| US-12097185-B2 | Compositions comprising ciprofloxacin and celecoxib | Active | 19-Oct-2021 | A61K31/415 |
NeuroSense Therapeutics Executive Team (8)
| Name | Title | Board Seat |
|---|---|---|
| Alon Ben-Noon | Chief Executive Officer & Founder | |
| Or Eisenberg | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | |
| Hagit Binder | Chief Operating Officer, Operations | |
| Niva Russek- Blum Ph.D | Chief Technology Officer | |
| Oron Yacoby-Zeevi Ph.D | Chief Scientific Officer & Board Member |
NeuroSense Therapeutics Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Caren Deardorf | Self | Board Member | |
| Cary Claiborne | Self | Board Member | |
| Christine Pellizzari JD | Self | Board Member | |
| Mark Leuchtenberger | Self | Chairman & Board Member | |
| Oron Yacoby-Zeevi Ph.D | NeuroSense Therapeutics | Chief Scientific Officer & Board Member |
NeuroSense Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NeuroSense Therapeutics FAQs
-
When was NeuroSense Therapeutics founded?
NeuroSense Therapeutics was founded in 2016.
-
Who is the founder of NeuroSense Therapeutics?
Alon Ben-Noon, Ariel Gordon, and Yossi Gross are the founders of NeuroSense Therapeutics.
-
Who is the CEO of NeuroSense Therapeutics?
Alon Ben-Noon is the CEO of NeuroSense Therapeutics.
-
Where is NeuroSense Therapeutics headquartered?
NeuroSense Therapeutics is headquartered in Cambridge, MA.
-
What is the size of NeuroSense Therapeutics?
NeuroSense Therapeutics has 16 total employees.
-
What industry is NeuroSense Therapeutics in?
NeuroSense Therapeutics’s primary industry is Drug Discovery.
-
Is NeuroSense Therapeutics a private or public company?
NeuroSense Therapeutics is a Public company.
-
What is NeuroSense Therapeutics’s stock symbol?
The ticker symbol for NeuroSense Therapeutics is NRSN.
-
What is the current stock price of NeuroSense Therapeutics?
As of 09-Oct-2024 the stock price of NeuroSense Therapeutics is $1.22.
-
What is the current market cap of NeuroSense Therapeutics?
The current market capitalization of NeuroSense Therapeutics is $24.2M.
-
Who are NeuroSense Therapeutics’s competitors?
Prilenia, Amylyx, Prothena, Alector, and AB Science are some of the 7 competitors of NeuroSense Therapeutics.
-
What is NeuroSense Therapeutics’s annual earnings per share (EPS)?
NeuroSense Therapeutics’s EPS for 12 months was -$0.65.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
